Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Sells $456,790.00 in Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Eben Tessari sold 17,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total transaction of $456,790.00. Following the sale, the chief operating officer now directly owns 109,975 shares in the company, valued at approximately $2,955,028.25. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Eben Tessari also recently made the following trade(s):

• On Monday, September 23rd, Eben Tessari sold 17,500 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $24.99, for a total transaction of $437,325.00.
• On Tuesday, August 27th, Eben Tessari sold 17,500 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $26.91, for a total value of $470,925.00.

Kiniksa Pharmaceuticals Stock Performance

NASDAQ:KNSA opened at $26.26 on Friday. Kiniksa Pharmaceuticals, Ltd. has a 1 year low of $14.12 and a 1 year high of $27.92. The stock has a market cap of $1.86 billion, a P/E ratio of 238.73 and a beta of 0.33. The stock has a 50-day simple moving average of $25.58 and a 200-day simple moving average of $21.94.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, July 23rd. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.03. Kiniksa Pharmaceuticals had a negative return on equity of 7.79% and a negative net margin of 3.10%. The firm had revenue of $108.30 million during the quarter, compared to the consensus estimate of $90.60 million. During the same period in the prior year, the company posted ($0.02) earnings per share. The firm’s quarterly revenue was up 51.5% compared to the same quarter last year. On average, equities research analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.29 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on KNSA. Jefferies Financial Group began coverage on Kiniksa Pharmaceuticals in a report on Friday, September 13th. They set a “buy” rating and a $40.00 price target on the stock. Wedbush upped their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 23rd. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $33.60.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. CWM LLC grew its holdings in shares of Kiniksa Pharmaceuticals by 443.0% during the third quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $61,000 after purchasing an additional 1,998 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals in the 1st quarter valued at about $71,000. nVerses Capital LLC purchased a new position in Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $80,000. Ashton Thomas Private Wealth LLC acquired a new position in Kiniksa Pharmaceuticals during the second quarter worth approximately $100,000. Finally, Lynx1 Capital Management LP purchased a new stake in Kiniksa Pharmaceuticals in the second quarter valued at approximately $177,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.